Hematology

Compared to the usual care, patients with HFpEF in the active arms demonstrated less improvement in peakVO2 when they had iron deficiency and lower values of ferritin and transferrin saturation, according to a new study.

Lower levels of selenoprotein P were associated with reduced hemoglobin, greater transferrin receptor 1, and an increased prevalence of anemia in a cohort of hospitalized heart failure patients.

Observational data from the ARIC study reveals that lower plasma levels correlate with an increased risk of incident heart failure and diastolic dysfunction.

Patients on maintenance hemodialysis classified as having a high erythropoietin resistance index had a greater risk of all-cause mortality.

Analysis finds measures of iron deficiency, including ferritin, serum iron, and transferrin, were linked to an increased likelihood of depression in young adult males but not females.

Results of the PRECISION trial suggest use of iron-whey-protein microspheres could aid in improving adherence to oral iron therapy as well as staving off adverse GI events.

Moderate-to-severe anemia decreased the likelihood of a favorable outcome after mechanical thrombectomy compared with no anemia.

A study of more than 140 adults with diabetes is providing additional insight into the prevalence of anemia among these patients as well as its association with changes in glycemic control.

A systematic review combined with a pair of case studies suggest men who discontinue the front-line treatment for conditions like polycythaemia vera may improve their fertility.

A new study demonstrated hemoglobin levels significantly increased with ziltivekimab, showing the monoclonal antibody has the potential to serve as a new treatment method for anemia.

Keli Coleman, MD, discusses findings from her research about the role of pain scores and opioids in predicting hospitalization and return visits in children with sickle cell disease and uncomplicated pain crises.

Presented at ASH 2023, a new study demonstrated physical activity does not increase bleeding for patients with hemophilia A as patients with low physical activity still experienced frequent bleeding.

Presented at ASH 2023, findings of a new study showed patients with sickle cell disease and venous thromboembolism have longitudinal worsening of left ventricular diastolic and right-sided cardiac function.

Phase 3 data presented at ASH 2023 show the gene therapy significantly reduced annualized bleeding rates and the number of total bleeds.

Final emergency department pain scores, opioid doses in the emergency department, and receipt of an opioid prescription at discharge predicted hospitalization and return visits.

Presented at ASH 2023, opioid use disorder in sickle cell disease patients with vaso-occlusive is associated with a longer hospital stay and greater cost.

Findings of a new study suggest COVID-19 does not serve as risk factor for the development of VTE in pediatric cancer patients.

Results showed treatment with iptacopan through 48 weeks caused hemoglobin-level increases, blood transfusion avoidance, and reductions in patient-reported fatigue.

Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.

Study results presented at the 2023 American Society of Hematology Annual Meeting and Exposition found equal immune tolerance induction success rates regardless of race/ethnicity.

The revised algorithm demonstrates 97% sensitivity in identifying pregnant patients with inherited bleeding disorders.

Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years.

New case-control data from ASH 2023 show a particularly increased link between sickle cell trait and monocytic and myeloid leukemia progression.

These findings presented at ASH show promise for future studies on GBT02601 as a potential alternative to voxelotor for sickle cell disease.

This new data on a European sickle cell disease cohort expands upon existing knowledge of the effects of HU on fertility, with the findings showing the benefits of cryopreservation.

Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.

Bezuclastinib, a targeted oral therapy, shows promise in reducing disease burden and improving symptoms by 50% or more in nonadvanced systemic mastocytosis patients, as revealed in the phase 2 SUMMIT trial data presented at ASH 2023.

A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.

A study followed a neonatal cohort with sickle cell disease for up to 20 years. The study demonstrated how hydroxyurea lowers the risk of high mortality.